Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO Sells $151,387.96 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White sold 2,804 shares of the firm’s stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $53.99, for a total transaction of $151,387.96. Following the completion of the sale, the chief financial officer now owns 59,155 shares of the company’s stock, valued at $3,193,778.45. The trade was a 4.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Akero Therapeutics Stock Up 3.8%

Shares of NASDAQ AKRO opened at $55.62 on Friday. The stock has a market capitalization of $4.43 billion, a P/E ratio of -14.83 and a beta of -0.16. The company has a 50-day moving average price of $43.96 and a 200-day moving average price of $40.36. Akero Therapeutics, Inc. has a 1 year low of $21.02 and a 1 year high of $58.40. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings results on Monday, May 12th. The company reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.01) by $1.91. On average, equities research analysts forecast that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on AKRO. Bank of America raised their price target on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a “buy” rating in a report on Tuesday, May 27th. Morgan Stanley restated an “overweight” rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. HC Wainwright raised their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Monday, March 3rd. Finally, Citigroup reduced their price target on shares of Akero Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Tuesday, May 13th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $82.50.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Northwest & Ethical Investments L.P. bought a new stake in Akero Therapeutics in the first quarter worth about $32,000. GF Fund Management CO. LTD. bought a new stake in Akero Therapeutics during the 4th quarter worth approximately $41,000. Sterling Capital Management LLC increased its holdings in Akero Therapeutics by 764.3% during the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company’s stock worth $50,000 after acquiring an additional 1,582 shares during the period. PNC Financial Services Group Inc. increased its holdings in shares of Akero Therapeutics by 30.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company’s stock worth $67,000 after buying an additional 390 shares during the last quarter. Finally, Quarry LP bought a new position in shares of Akero Therapeutics in the 4th quarter worth $83,000.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.